Beacon Pointe Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Beacon Pointe Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,274	Closed	-$765K	–	1260
2022 Q1	$765K	Buy	+7,274	New	+$709K	0.01%	687
2021 Q3	–	Sell	-3,146	Closed	-$295K	–	996
2021 Q2	$295K	Buy	+3,146	New	+$290K	0.01%	659

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Beacon Pointe Advisors's HZNP Position: Q2 2022 in Review

Beacon Pointe Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 7,274 shares — an estimated $765K sold.

Beacon Pointe Advisors first reported a position in HZNP in Q2 2021 and held it in 2 quarters. The position peaked at $765K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Beacon Pointe Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Beacon Pointe Advisors sold 7,274 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $765K.
Beacon Pointe Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 2 quarters.
Beacon Pointe Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $765K in Q1 2022.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Beacon Pointe Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.